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Figure S1. Supplementary Data. (a) The comparison of pneumococcal capsule synthesis and E. coli 
LPS/glycoprotein synthesis. (b) & (c) Sera from mice injected with geOMVs displaying pneumococcal 
serotype 14 capsule antigens is specific for S. pneumoniae serotype 14. Mouse sera from 10 animals 
(Day 21) were incubated in wells of ELISAs plates seeded with whole cell S. pneumoniae serotype 9V (b) 
or 14 (c). As a negative control, sera from 4 mice injected with empty control OMVs was tested on the 
same plate layout. Means from each group were compared and significant differences were found 
between control OMVs sera and CPS14 geOMVs sera in (c) (* p-value < 0.0001). No significant 
differences were found between groups in (b) (NS p-value = 0.45). Error bars are SD and p-values were 
calculated by the unpaired t-test. (d) ELISA data of the IgY response of chicken vaccinated with 
Campylobacter geOMVs. Each symbol represents data of one chicken and the median is indicated with a 
line. Animal sera (Day 28) was used at a dilution of 1:10. 
 

